利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

120 条记录 (耗时 0.052 秒)

    Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure
    71.
    发明申请
    Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure 有权
    向中枢神经系统递送交感神经心血管药物以对抗心力衰竭和与心力衰竭相关的病理

    公开(公告)号：US20050177135A1

    公开(公告)日：2005-08-11

    申请号：US10773965

    申请日：2004-02-06

    申请人： Keith Hildebrand ,  Michael Ujhelyi ,  Xiaohong Zhou ,  Daniel Sigg ,  Linda Page

    发明人： Keith Hildebrand ,  Michael Ujhelyi ,  Xiaohong Zhou ,  Daniel Sigg ,  Linda Page

    IPC分类号： A61B5/02 ,  A61M5/142 ,  A61M5/168 ,  A61M5/172 ,  A61N1/39 ,  A61K9/22

    CPC分类号： A61M5/142 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3523 ,  A61M2230/00 ,  A61M2230/04 ,  A61M2230/63 ,  A61N1/3962

    摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.

    摘要翻译： 由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解症状，另外治疗与HF有关的心力衰竭（HF）和病理学。 药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。 患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与HF相关的生理学参数（或与HF相关的病理学）和触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。 交感神经心血管药剂是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂组成的组之一，例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫西康定，甲基多巴，甲苯噻嗪，胍法辛，美托咪定，美托咪定和 右美托咪定。

    Method for acquiring spatially and spectrally selective MR images
    72.
    发明授权
    Method for acquiring spatially and spectrally selective MR images 失效
    用于获取空间和频谱选择性MR图像的方法

    公开(公告)号：US06175236B1

    公开(公告)日：2001-01-16

    申请号：US09047822

    申请日：1998-03-25

    申请人： Xiaohong Zhou ,  Matthew A. Bernstein

    发明人： Xiaohong Zhou ,  Matthew A. Bernstein

    IPC分类号： G01V300

    CPC分类号： G01R33/446 ,  G01R33/5613

    摘要： A method for acquiring spatially and spectrally selective MR images by means of an MR imaging system includes the step of selecting an SPSP pulse sequence, comprising a succession of RF sub-pulses and an oscillatory gradient magnetic field, which is disposed to select a slice through a subject. The method further includes measuring specified parameters of a perturbation magnetic field associated with the imaging system, and deriving an expression for the perturbation field from respective measured parameters and from the oscillatory gradient magnetic field. A specified ideal frequency modulation function, associated with the SPSP sequence, is disposed to offset the slice to a particular spatially localized region of the subject. The SPSP pulse sequence is modified by adjusting the frequency modulation function in specified corresponding relationship with the expression. The modified SPSP pulse sequence is then applied to the subject to excite a selected spectral species in the spatially localized region, while substantially reducing signal intensity loss resulting from the perturbation magnetic field.

    摘要翻译： 用于通过MR成像系统获取空间和频谱选择性MR图像的方法包括选择包括一系列RF子脉冲和振荡梯度磁场的SPSP脉冲序列的步骤，其被设置为选择切片通过 课程。 该方法还包括测量与成像系统相关联的扰动磁场的指定参数，以及从相应的测量参数和振荡梯度磁场导出扰动场的表达式。 设置与SPSP序列相关联的指定的理想频率调制功能，以将切片偏移到对象的特定空间局部区域。 通过调整与规定的对应关系的频率调制函数来修改SPSP脉冲序列。 然后将经修改的SPSP脉冲序列应用于受试者以激发空间局部区域中的选定光谱物种，同时显着降低由扰动磁场引起的信号强度损失。

    COLORED, DYNAMIC, AND AMPLIFIED SAFETY FILM
    77.
    发明申请
    COLORED, DYNAMIC, AND AMPLIFIED SAFETY FILM 有权
    彩色，动态和放大安全膜

    公开(公告)号：US20150198749A1

    公开(公告)日：2015-07-16

    申请号：US14419151

    申请日：2012-08-03

    申请人： Yan Ye ,  Linsen Chen ,  Su Shen ,  Yun Zhou ,  Xiaohong Zhou ,  Jin Hu ,  Pengfei Zhu ,  Donglin Pu ,  Guojun Wei

    发明人： Yan Ye ,  Linsen Chen ,  Su Shen ,  Yun Zhou ,  Xiaohong Zhou ,  Jin Hu ,  Pengfei Zhu ,  Donglin Pu ,  Guojun Wei

    IPC分类号： G02B3/00 ,  G02B5/28

    CPC分类号： G02B3/0056 ,  B42D25/324 ,  B42D25/342 ,  B42D25/351 ,  B42D25/373 ,  G02B5/18 ,  G02B5/28 ,  G02B5/284 ,  G02B27/12

    摘要： A colored, dynamic, and amplified security film includes a micro lens array layer, a base material layer, and a micro graphic layer. The layers meet the condition of Moore amplified imaging; the micro graphic layer is formed by a background area and a graphic area; the graphic area is distributed in the background area; the micro graphic layer includes a semi-transparent and semi-reflective metal layer, a medium layer, and a metal film layer successively from top to bottom; the metal film layer is of a planar structure; the thickness of the medium layer in the graphic area is greater than the thickness of the medium layer in the background area; and the thicknesses of semi-transparent and semi-reflective metal layers are consistent.

    摘要翻译： 彩色，动态和放大的安全膜包括微透镜阵列层，基材层和微图形层。 这些层符合摩尔放大成像条件; 微图形层由背景区域和图形区域形成; 图形区域分布在背景区域; 微图形层从上到下依次包括半透明和半反射金属层，介质层和金属膜层; 金属膜层是平面结构的; 图形区域中的介质层的厚度大于背景区域中介质层的厚度; 并且半透明和半反射金属层的厚度是一致的。

    Detection of T-wave alternans phase reversal for arrhythmia prediction and sudden cardiac death risk stratification
    78.
    发明授权
    Detection of T-wave alternans phase reversal for arrhythmia prediction and sudden cardiac death risk stratification 有权
    检测心律失常预测和心源性猝死危险分层的T波交替相逆转

    公开(公告)号：US08620414B2

    公开(公告)日：2013-12-31

    申请号：US12749753

    申请日：2010-03-30

    申请人： Raja N. Ghanem ,  Xiaohong Zhou

    发明人： Raja N. Ghanem ,  Xiaohong Zhou

    IPC分类号： A61B5/0452

    CPC分类号： A61B5/0452 ,  A61B5/02405 ,  A61B5/7264 ,  A61B5/7275 ,  A61N1/36507 ,  G06F19/00

    摘要： An implantable medical device and associated method for classifying a patient's risk for arrhythmias by sensing a cardiac electrogram (EGM) signal and selecting a first pair of T-wave signals and a second pair of T-wave signals. A first difference between the two T-wave signals of the first pair is compared to a second difference between the two T-wave signals of the second pair. A T-wave alternans phase reversal is detected in response to comparing the first difference and the second difference, and the patient's arrhythmia risk is classified in response to detecting the phase reversal.

    摘要翻译： 一种用于通过感测心电图（EGM）信号和选择第一对T波信号和第二对T波信号来分类患者心律失常风险的可植入医疗装置和相关方法。 将第一对的两个T波信号之间的第一个差异与第二对的两个T波信号之间的第二个差值进行比较。 响应于比较第一个差异和第二个差异，检测到T波交替相位逆转，并且响应于检测相位反转来分类患者的心律失常风险。

    INHIBITION OF RETINAL CELL DEGENERATION OR NEOVASCULARIZATION BY CERIUM OXIDE NANOPARTICLES
    80.
    发明申请
    INHIBITION OF RETINAL CELL DEGENERATION OR NEOVASCULARIZATION BY CERIUM OXIDE NANOPARTICLES 审中-公开
    通过氧化氮纳米颗粒抑制细胞衰老或新生血管细胞

    公开(公告)号：US20110111007A1

    公开(公告)日：2011-05-12

    申请号：US12772523

    申请日：2010-05-03

    申请人： James F. McGinnis ,  Xiaohong Zhou ,  Lily L. Wong ,  Sudipta Seal

    发明人： James F. McGinnis ,  Xiaohong Zhou ,  Lily L. Wong ,  Sudipta Seal

    IPC分类号： A61F2/14 ,  A61K33/24 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P19/02 ,  A61P1/00 ,  A61P17/00 ,  A61K9/14 ,  B82Y5/00

    CPC分类号： A61K33/00

    摘要： The presently claimed and disclosed inventive concept(s) provides methods for reducing, reversing or inhibiting retinal cell degeneration, or neovascularization in tissues of a mammalian subject having a pathological condition involving neovascularization, by administration in vivo of nanoceria particles (cerium oxide nanoparticles) to the subject. The method of the presently claimed and disclosed inventive concept(s) is useful, for example, for reducing, treating, reversing or inhibiting degeneration of retinal cells such as photoreceptor cells or neovascularization in ocular tissue such as the retina, macula or cornea; or other tissues such as, but not limited to, skin, synovial tissue, intestinal tissue, or bone. In addition, the method of the presently claimed and disclosed inventive concept(s) is useful for reducing or inhibiting neovascularization in a neoplasm (tumors), which can be benign or malignant and, where malignant, can be a metastatic neoplasm. As such, the presently claimed and disclosed inventive concept(s) is directed to using compositions containing nanoceria particles to reduce, treat, reverse or inhibit angiogenesis in a mammalian subject.

    摘要翻译： 目前要求权利要求和公开的发明构思通过在体内施用纳米颗粒（二氧化铈纳米颗粒）至哺乳动物受试者具有新生血管形成病理状态的组织中的视网膜细胞变性或新生血管形成， 主题。 目前权利要求和公开的发明构思的方法可用于例如减少，治疗，逆转或抑制视网膜细胞如感光细胞的变性或眼组织如视网膜，黄斑或角膜中的新生血管形成; 或其它组织，例如但不限于皮肤，滑膜组织，肠组织或骨。 此外，本发明权利要求和公开的发明构思的方法可用于减少或抑制肿瘤（肿瘤）中的新生血管形成，所述肿瘤可能是良性或恶性的，并且恶性肿瘤可以是转移性肿瘤。 因此，目前要求保护和公开的发明构思涉及使用含有纳米颗粒的组合物来减少，治疗，逆转或抑制哺乳动物受试者的血管发生。